JP7544815B2 - Ｃｄ７３阻害剤 - Google Patents

Ｃｄ７３阻害剤 Download PDF

Info

Publication number
JP7544815B2
JP7544815B2 JP2022525101A JP2022525101A JP7544815B2 JP 7544815 B2 JP7544815 B2 JP 7544815B2 JP 2022525101 A JP2022525101 A JP 2022525101A JP 2022525101 A JP2022525101 A JP 2022525101A JP 7544815 B2 JP7544815 B2 JP 7544815B2
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500483A (ja
JP2023500483A5 (https=
JPWO2021087136A5 (https=
Inventor
ドュ，シャオフイ
エクステロウィッツ，ジョン
アール． ファンティン，ヴァレリア
サン，ダチン
イェ，チョウピン
ムーア，ジャレド
ザヴォロティンスカヤ，タチアナ
アール． ブランク，ブライアン
リュウ，ヨサップ
ウー，ケジア
ズー，リュウシェン
ファム，ジョニー
カワイ，ヒロユキ
イェ，チェン－ホン
Original Assignee
オリック ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリック ファーマシューティカルズ，インク． filed Critical オリック ファーマシューティカルズ，インク．
Publication of JP2023500483A publication Critical patent/JP2023500483A/ja
Publication of JP2023500483A5 publication Critical patent/JP2023500483A5/ja
Publication of JPWO2021087136A5 publication Critical patent/JPWO2021087136A5/ja
Priority to JP2024135814A priority Critical patent/JP7688769B2/ja
Application granted granted Critical
Publication of JP7544815B2 publication Critical patent/JP7544815B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022525101A 2019-10-30 2020-10-29 Ｃｄ７３阻害剤 Active JP7544815B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135814A JP7688769B2 (ja) 2019-10-30 2024-08-15 Ｃｄ７３阻害剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962928138P 2019-10-30 2019-10-30
US62/928,138 2019-10-30
US202062987806P 2020-03-10 2020-03-10
US62/987,806 2020-03-10
US202063088646P 2020-10-07 2020-10-07
US63/088,646 2020-10-07
PCT/US2020/057996 WO2021087136A1 (en) 2019-10-30 2020-10-29 Cd73 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135814A Division JP7688769B2 (ja) 2019-10-30 2024-08-15 Ｃｄ７３阻害剤

Publications (4)

Publication Number Publication Date
JP2023500483A JP2023500483A (ja) 2023-01-06
JP2023500483A5 JP2023500483A5 (https=) 2023-10-13
JPWO2021087136A5 JPWO2021087136A5 (https=) 2023-10-13
JP7544815B2 true JP7544815B2 (ja) 2024-09-03

Family

ID=75686256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525101A Active JP7544815B2 (ja) 2019-10-30 2020-10-29 Ｃｄ７３阻害剤
JP2024135814A Active JP7688769B2 (ja) 2019-10-30 2024-08-15 Ｃｄ７３阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135814A Active JP7688769B2 (ja) 2019-10-30 2024-08-15 Ｃｄ７３阻害剤

Country Status (19)

Country Link
US (7) US11530236B2 (https=)
EP (2) EP4051688B1 (https=)
JP (2) JP7544815B2 (https=)
KR (2) KR102653726B1 (https=)
CN (2) CN116854758A (https=)
AU (1) AU2020375914B2 (https=)
CA (1) CA3159248C (https=)
DK (1) DK4051688T3 (https=)
ES (1) ES3034168T3 (https=)
FI (1) FI4051688T3 (https=)
HU (1) HUE072504T2 (https=)
IL (2) IL308293B2 (https=)
MX (1) MX2022005256A (https=)
PL (1) PL4051688T3 (https=)
PT (1) PT4051688T (https=)
SI (1) SI4051688T1 (https=)
TW (1) TWI830962B (https=)
WO (1) WO2021087136A1 (https=)
ZA (1) ZA202204941B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024164093A (ja) * 2019-10-30 2024-11-26 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
WO2024059609A1 (en) * 2022-09-14 2024-03-21 Oric Pharmaceuticals, Inc. Pharmaceutical forms of a cd73 inhibitor
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2024076873A1 (en) * 2022-10-03 2024-04-11 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2025111247A1 (en) * 2023-11-20 2025-05-30 Oric Pharmaceuticals, Inc. Treatment of refractory multiple myeloma
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513955A (ja) 2014-04-25 2017-06-01 ビテ・ファーマシューティカルズ・インコーポレイテッドＶｉｔａｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
WO2017120508A1 (en) 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
WO2018067424A1 (en) 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
WO2018094148A1 (en) 2016-11-18 2018-05-24 Arcus Biosciences, Inc. Inhibitors of cd73-mediated immunosuppression
WO2018183635A1 (en) 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
JP2021522280A (ja) 2018-04-30 2021-08-30 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023991A (en) 1911-07-29 1912-04-23 Firm B Byers Anti-rail-creeper and splice-bar.
EP0477454A1 (en) 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
EA036379B1 (ru) * 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
TWI767937B (zh) 2016-09-09 2022-06-21 美商卡利泰拉生物科技公司 外核苷酸酶抑制劑及其使用方法
JP7138351B2 (ja) 2016-12-22 2022-09-16 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019129059A1 (zh) 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
AU2019288495B2 (en) 2018-06-21 2024-02-08 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
EP3843714B1 (en) 2018-08-27 2025-11-12 Arcus Biosciences, Inc. Cd73 inhibitors
KR20220024629A (ko) 2019-06-20 2022-03-03 칼리테라 바이오사이언시즈, 인코포레이티드 엑토뉴클레오티다제 억제제 및 이의 사용 방법
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
HUE072504T2 (hu) 2019-10-30 2025-11-28 Oric Pharmaceuticals Inc CD73-inhibitorok

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513955A (ja) 2014-04-25 2017-06-01 ビテ・ファーマシューティカルズ・インコーポレイテッドＶｉｔａｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
WO2017120508A1 (en) 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
WO2018067424A1 (en) 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
WO2018094148A1 (en) 2016-11-18 2018-05-24 Arcus Biosciences, Inc. Inhibitors of cd73-mediated immunosuppression
WO2018183635A1 (en) 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
JP2021522280A (ja) 2018-04-30 2021-08-30 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024164093A (ja) * 2019-10-30 2024-11-26 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤
JP7688769B2 (ja) 2019-10-30 2025-06-04 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤

Also Published As

Publication number Publication date
KR20240042573A (ko) 2024-04-02
IL292570B1 (en) 2023-12-01
BR112022008365A2 (pt) 2023-03-28
JP7688769B2 (ja) 2025-06-04
US20210214387A1 (en) 2021-07-15
NZ788133A (en) 2024-03-22
US20250034198A1 (en) 2025-01-30
IL292570B2 (en) 2024-04-01
KR20220088786A (ko) 2022-06-28
KR102653726B1 (ko) 2024-04-01
PT4051688T (pt) 2025-06-30
AU2020375914B2 (en) 2024-05-23
US11028120B2 (en) 2021-06-08
AU2020375914A1 (en) 2022-06-02
CN114929721A (zh) 2022-08-19
US20220411459A1 (en) 2022-12-29
TWI830962B (zh) 2024-02-01
SI4051688T1 (sl) 2025-08-29
CN116854758A (zh) 2023-10-10
EP4596048A2 (en) 2025-08-06
IL308293B1 (en) 2025-08-01
KR102727229B1 (ko) 2024-11-06
JP2023500483A (ja) 2023-01-06
ZA202204941B (en) 2024-10-30
US11530236B2 (en) 2022-12-20
US20210130389A1 (en) 2021-05-06
US20260042794A1 (en) 2026-02-12
IL308293A (en) 2024-01-01
FI4051688T3 (fi) 2025-06-27
IL292570A (en) 2022-06-01
EP4051688A4 (en) 2024-03-06
HUE072504T2 (hu) 2025-11-28
EP4051688A1 (en) 2022-09-07
EP4596048A3 (en) 2025-11-19
ES3034168T3 (en) 2025-08-13
EP4051688B1 (en) 2025-04-23
US20230131747A1 (en) 2023-04-27
PL4051688T3 (pl) 2025-09-22
DK4051688T3 (da) 2025-06-30
CA3159248A1 (en) 2021-05-06
US12454544B2 (en) 2025-10-28
MX2022005256A (es) 2022-08-25
TW202130353A (zh) 2021-08-16
IL308293B2 (en) 2025-12-01
CA3159248C (en) 2024-05-28
CN114929721B (zh) 2023-07-18
US20210130390A1 (en) 2021-05-06
US11130778B2 (en) 2021-09-28
US12018043B2 (en) 2024-06-25
US12577272B2 (en) 2026-03-17
JP2024164093A (ja) 2024-11-26
BR122023021184A2 (pt) 2024-02-27
WO2021087136A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7688769B2 (ja) Ｃｄ７３阻害剤
JP7489323B2 (ja) Ｃｄ７３阻害剤
EA046660B1 (ru) Ингибиторы cd73
BR112022008365B1 (pt) Compostos inibidores de cd73, composição farmacêutica que oscompreende, método de inibição de cd73 in vitro e uso dos referidos compostos
BR122023021184B1 (pt) Compostos inibidores de cd73, composição farmacêutica que os compreende, método de inibição de cd73 in vitro e uso dos referidos compostos
HK40081385A (en) Cd73 inhibitors
HK40081385B (en) Cd73 inhibitors
HK40079937B (zh) Cd73抑制剂
HK40079937A (en) Cd73 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220510

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231004

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240822

R150 Certificate of patent or registration of utility model

Ref document number: 7544815

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150